Similar findings were shown in patients with triple negative and HER-2/neu positive breast cancer enrolled on a phase III, randomized FinHER trial that tested different adjuvant chemotherapy regiments with or without trastuzumab. Here, ERBB2 is linked to breast carcinoma.